|
| |
AVI BioPharmaAVI BioPharma is an emerging biopharmaceutical company and a pioneer in the development of therapeutic products based upon three platform technologies: - therapeutic cancer vaccines,
- gene-targeted drugs (antisense), and,
- drug delivery technologies.
The Company focuses its three platform technologies on two important clinical areas, cancer and cardiovascular disease. The Company is in late-stage development with Avicine, its cancer vaccine, which the Company believes may be applicable to many cancer types. The Company also has developed Neu-Genes(R), a patented class of antisense compounds, which may prove to be useful in the treatment of a wide range of human diseases. The Company has developed a new intracellular drug delivery technology, CytoPorter(TM), which may be useful with many FDA-approved drugs as well as with drugs in
development.
| Contact Details: |
| ONE SW COLUMBIA STREET, SUITE 1105 |
| Portland |
| |
| 97258 |
| United States of America |
| Tel: | 503 227 0554 |
| Fax: | 503 227 0751 |
| Email: | avi@avibio.com |
| WWW: | www.avibio.com/
|
| |
Recent Publications by AVI BioPharma: |  |
Cationic phosphorodiamidate morpholino oligomers efficiently prevent growth of Escherichia coli in vitro and in vivo.
Objectives Phosphorodiamidate morpholino oligomers (PMOs) are uncharged... | 4th November, 2009
| AVI BioPharma, Inc., 4574 SW Research Way, Suite 200, Corvallis, OR 97333,
| J Antimicrob Chemother. 2009 Nov 1.
DOI Direct Link |
Peptide-morpholino conjugate: a promising therapeutic for Duchenne muscular dystrophy.
Steric-blocking oligos can correct reading frame errors or skip premature... | 23rd October, 2009
| AVI BioPharma, Corvallis,
| Ann N Y Acad Sci. 2009 Sep;1175:55-60.
DOI Direct Link |
Antisense targeting of cFLIP sensitizes activated T cells to undergo apoptosis and desensitizes responses to contact dermatitis.
Contact dermatitis is the result of inflammatory responses mediated by... | 1st August, 2009
| Department of Biology, AVI BioPharma Inc., Corvallis, Oregon, USA.
| J Invest Dermatol. 2009 Aug;129(8):1945-53. Epub 2009 Feb 19.
DOI Direct Link |
Splicing in the immune system: potential targets for therapeutic intervention by antisense-mediated alternative splicing.
Alternative splicing of pre-mRNA leads to variation in the exons that form... | 12th June, 2009
| AVI BioPharma, 4575 SW Research Way, Suite 200, Corvallis, OR 97333, USA.
| Curr Opin Mol Ther. 2009 Apr;11(2):124-32.
|
RNA-based therapeutics--from design to the clinic.
Alternative splicing of pre-mRNA leads to variation in the exons that form... | 12th June, 2009
| AVI BioPharma, 4575 SW Research Way, Corvallis, OR 97333, USA.
| Curr Opin Mol Ther. 2009 Apr;11(2):107.
|
→View more AVI BioPharma research publications. |
Press Releases on AVI BioPharma:
|
 |
| BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company |
6th August, 2009 |
BioMed Realty Trust, Inc. |
-- On July 8, 2009, Arena Pharmaceuticals, Inc., the company's tenth
largest tenant, raised approximately $50 million in net proceeds from a
common stock offering. In
|
| Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting |
20th April, 2009 |
Quark Pharmaceuticals, Inc. |
FREMONT, Calif., April 20 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today
|
| SuperGen Reports 2008 Fourth Quarter and Year-End Financial Results |
2nd March, 2009 |
SuperGen Inc. |
SUPERGEN, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
|
| SuperGen Reports 2008 Third Quarter Financial Results |
4th November, 2008 |
SuperGen, Inc. |
DUBLIN, Calif., Nov. 4 /PRNewswire-FirstCall/ -- SuperGen, Inc.
(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and
development of novel cancer therapies, today announced
|
| SuperGen Reports 2008 Second Quarter Financial Results |
4th August, 2008 |
SuperGen, Inc. |
DUBLIN, Calif., Aug. 4 /PRNewswire-FirstCall/ -- SuperGen, Inc.
(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therapies for solid
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 902 times since April 2007, the link to the organisation's website has been followed 81 times Recent Search Terms used to find this page: immune system avi | Splicing in the immune system potential targets for therapeutic intervention by antisense-mediated alternative splicing. | pmo antisense patents | avi biopharma Biology Department corvallis | Curr Opin Mol Ther. 2009 Apr 11 2 124-32. | AVI morpholino | Cellular Uptake of Neutral Phosphorodiamidate Morpholino Oligomers. | patent for phosphorodiamidate morpholino oligomers | avi pharmaceuticals | avi pharmaceuticals | . Search for more companies in Portland Search for more companies in This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for AVI BioPharma |
